Trevi Therapeutics Announces Oral Presentation Accepted at the CHEST 2026 Annual Meeting
Trevi Therapeutics announced that results from the Phase 2b CORAL trial of Haduvio (oral nalbuphine ER) in IPF-related chronic cough were accepted for an oral presentation at the CHEST 2026 Annual Meeting. The presentation, titled on patient-reported outcomes showing early and sustained improvement, will be delivered by Philip Molyneaux on October 20 in the ILD Treatment Updates session.
Key figures
- Drug Name
- Haduvio (oral nalbuphine extended-release)
- Phase Of Trial
- Phase 2b
- Trial name
- CORAL
- Doses tested
- ["27 mg","54 mg","108 mg twice daily"]
- Us ipf patients
- ~140,000
- Us rcc patients
- ~2-3 million
- Treatment duration
- 6 weeks
- Patients randomized
- 165
- Us non ipf ild patients
- ~228,000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.